$NVNO

Duhay Francis sold $1K of NVNO

Duhay Francis sold 140 shares of enVVeno Medical Corp (NVNO) at $10.30 on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Duhay Francis
Published Jun 12, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NVNO
Neutral
high confidence
Mentioned
$NVNO
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NVNONeutralLow
01

Why it matters

A director open-market sale of 140 shares occurred on 2026-06-11; the plan is pre-arranged under Rule 10b5-1, which generally limits interpretive weight.

02

Market read

Primarily a sentiment/flow datapoint; no new fundamental catalyst is disclosed.

03

What to watch

The article provides only the transaction details; without context on total insider holdings, frequency of sales, or any concurrent corporate events, the signal is weak.

Relevance 2/10Novelty 2/10Timing: Filed 2026-06-12; sale executed 2026-06-11

Background

The article summarizes an SEC Form 4 insider transaction for enVVeno Medical Corp (NVNO).

Company-level read

Ticker impact

$NVNONeutralHigh confidence
Context

Director Duhay Francis sold 140 shares of enVVeno Medical Corp on 2026-06-11 under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment/flow rather than a new catalyst.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with a stated 10b5-1 pre-arranged plan and small share count/value, with no accompanying operational or regulatory development in the text.

Market effects

No sector read-through; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution; traders may watch for follow-on sales or other filings.

Key entities

  • enVVeno Medical Corp

    Company whose director insider sale is disclosed on SEC Form 4.

  • Duhay Francis

    Director who sold 140 shares under a pre-arranged 10b5-1 plan.

Related articles

$NVNOMedAI 8/10

enVVeno Medical Corporation: enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve

enVVeno Medical (NASDAQ:NVNO) reported Q2 2026 results and said the FDA granted IDE approval to start its TAVVE pivotal trial for its enVVe System. The company expects enrollment to begin in H2 2026 with about 230 patients across up to 40 sites. Cash and investments were about $21.5M at June 30, 2026, with Q2 net loss of $3.6M.

$NVNOMed

enVVeno Medical Corporation: enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial

enVVeno Medical (NASDAQ:NVNO) said the U.S. Patent Office issued U.S. Patent No. 12,575,932 covering components and use methods of its enVVe transcatheter replacement venous valve system for deep venous insufficiency. The company links this to prior FDA IDE approval for its TAVVE pivotal trial, with enrollment to start and first patient data expected by end of Q4 2026.